Peer review reports
From: Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors
Original Submission |
6 Jun 2018 |
Submitted |
Original manuscript
|
9 Jul 2018 |
Author responded |
Author comments - Wei Xue
|
Resubmission - Version 2 |
9 Jul 2018 |
Submitted |
Manuscript version 2
|
18 Oct 2018 |
Author responded |
Author comments - Liancheng Fan
|
Resubmission - Version 3 |
18 Oct 2018 |
Submitted |
Manuscript version 3
|
Publishing |
26 Oct 2018 |
Editorially accepted |
|
3 Dec 2018 |
Article published |
10.1186/s12894-018-0416-6
|
Learn about peer review